Galiximab

Drug Profile

Galiximab

Alternative Names: IDEC 114; IDEC 114-20

Latest Information Update: 08 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD80 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Discontinued Autoimmune disorders; Non-Hodgkin's lymphoma; Psoriasis

Most Recent Events

  • 04 Feb 2011 Galiximab is available for licensing as of 04 Feb 2011. www.biogenidec.com
  • 09 Dec 2008 Efficacy and adverse events data from a long-term follow up of a phase II trial in Non-Hodgkin's lymphoma presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
  • 30 Jan 2007 Discontinued - Phase-II for Autoimmune disorders in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top